(Q36177726)

12 August 2017

Liver enzymes elevation after HAART in HIV-HCV co-infection (English)

1 reference

12 August 2017

Servin-Abad L

1

1 reference

12 August 2017

Molina E

2

1 reference

12 August 2017

Baracco G

3

1 reference

12 August 2017

Arosemena L

4

1 reference

12 August 2017

Regev A

5

1 reference

12 August 2017

Jeffers L

6

1 reference

12 August 2017

Schiff E

7

1 reference

12 August 2017

1 July 2005

1 reference

Journal of Viral Hepatitis

12 August 2017

1 reference

12 August 2017

12

1 reference

12 August 2017

4

1 reference

12 August 2017

429-434

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Investigation of chronic hepatitis C infection in individuals with haemophilia: assessment of invasive and non-invasive methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Characteristics of patients with dual infection by hepatitis B and C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00617.X

10.1111/J.1365-2893.2005.00617.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference